Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Split Viewer
Dong Kee Jang1, Sang Hyub Lee2
Correspondence to: Sang Hyub Lee, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea, Tel: +82-2-2072-4892, Fax: +82-2-762-9662, E-mail: gidoctor@snuh.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2018;12(3):225-226. https://doi.org/10.5009/gnl18103
Published online May 15, 2018, Published date May 31, 2018
Copyright © Gut and Liver.
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is the established standard method for the histological diagnosis of various gastrointestinal malignancies and peri-intestinal structures.1 Peri-intestinal structures include lymph nodes, masses in the pancreas, liver, adrenal gland, and bile duct that are accessible from the gastrointestinal tract. EUS-FNA is indispensable especially in the diagnosis of pancreatic malignancies. Moreover, as the procedure has evolved, it has become possible to perform various magic interventions by modifying EUS-FNA. Therefore, the applications of EUS including EUS-FNA are getting much more attention worldwide. The more often it is performed, the more attention is needed to its complications.
Bleeding is one of the significant adverse events after EUS-FNA. The overall adverse event associated with EUS-FNA was reported to be 0.98% including a bleeding rate of 0.13% (14/10,941) according to a recent meta-analysis.2 EUS-FNA is defined as a high-risk procedure in the guidelines of the European and American Society of Gastrointestinal Endoscopy.3,4 However, the basis of these guidelines is relatively weak since most relevant studies were retrospective, and there were few studies on the risk of bleeding in patients taking antithrombotic agents. Kawakubo
A recent retrospective study on the similar subject reported that the overall bleeding rate was 0.9% (7/742).6 In detail, 131 patients (17.7%) were on antithrombotic therapy in 742 patients and six of seven bleeding occurred in patients who did not take antithrombotic agents. Bleeding occurred in one patient (1.6%) among the 61 patients who maintained use of aspirin or cilostazol, and no bleeding was detected in 62 patients who had discontinued antithrombotic agents. Based on these results, the authors concluded that the bleeding rate was low even in patients who underwent EUS-FNA while continuing aspirin or cilostazol. However, this study was a retrospective study with a small number of patients. So, it is difficult to generalize the results. There has been a similar study in the past. Kien-Fong Vu
The American and European guidelines recommend that aspirin should not be discontinued prior to EUS-FNA regardless of thrombotic risk, but thienopyridine and anticoagulants should be discontinued before the procedure.3,4 However, Kawakubo
No potential conflict of interest relevant to this article was reported.
Gut and Liver 2018; 12(3): 225-226
Published online May 31, 2018 https://doi.org/10.5009/gnl18103
Copyright © Gut and Liver.
Dong Kee Jang1, Sang Hyub Lee2
1Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea, 2Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Correspondence to:Sang Hyub Lee, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea, Tel: +82-2-2072-4892, Fax: +82-2-762-9662, E-mail: gidoctor@snuh.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is the established standard method for the histological diagnosis of various gastrointestinal malignancies and peri-intestinal structures.1 Peri-intestinal structures include lymph nodes, masses in the pancreas, liver, adrenal gland, and bile duct that are accessible from the gastrointestinal tract. EUS-FNA is indispensable especially in the diagnosis of pancreatic malignancies. Moreover, as the procedure has evolved, it has become possible to perform various magic interventions by modifying EUS-FNA. Therefore, the applications of EUS including EUS-FNA are getting much more attention worldwide. The more often it is performed, the more attention is needed to its complications.
Bleeding is one of the significant adverse events after EUS-FNA. The overall adverse event associated with EUS-FNA was reported to be 0.98% including a bleeding rate of 0.13% (14/10,941) according to a recent meta-analysis.2 EUS-FNA is defined as a high-risk procedure in the guidelines of the European and American Society of Gastrointestinal Endoscopy.3,4 However, the basis of these guidelines is relatively weak since most relevant studies were retrospective, and there were few studies on the risk of bleeding in patients taking antithrombotic agents. Kawakubo
A recent retrospective study on the similar subject reported that the overall bleeding rate was 0.9% (7/742).6 In detail, 131 patients (17.7%) were on antithrombotic therapy in 742 patients and six of seven bleeding occurred in patients who did not take antithrombotic agents. Bleeding occurred in one patient (1.6%) among the 61 patients who maintained use of aspirin or cilostazol, and no bleeding was detected in 62 patients who had discontinued antithrombotic agents. Based on these results, the authors concluded that the bleeding rate was low even in patients who underwent EUS-FNA while continuing aspirin or cilostazol. However, this study was a retrospective study with a small number of patients. So, it is difficult to generalize the results. There has been a similar study in the past. Kien-Fong Vu
The American and European guidelines recommend that aspirin should not be discontinued prior to EUS-FNA regardless of thrombotic risk, but thienopyridine and anticoagulants should be discontinued before the procedure.3,4 However, Kawakubo
No potential conflict of interest relevant to this article was reported.
pISSN 1976-2283
eISSN 2005-1212
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
| Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
| Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
| Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
| Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
PDF
Standard view
Export citation
Share 
